There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biogen (BIIB – Research Report), Catalyst Pharma (CPRX – Research Report) and Nemaura Medical (NMRD – Research Report) with bullish sentiments.
Biogen (BIIB)
In a report released today, Ami Fadia from Needham reiterated a Buy rating on Biogen, with a price target of $325.00. The company’s shares closed last Tuesday at $291.88, close to its 52-week high of $311.88.
According to TipRanks.com, Fadia is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $318.75 average price target, implying a 9.2% upside from current levels. In a report issued on January 10, RBC Capital also maintained a Buy rating on the stock with a $362.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Catalyst Pharma (CPRX)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Catalyst Pharma today and set a price target of $24.00. The company’s shares closed last Tuesday at $16.12.
According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Catalyst Pharma is a Strong Buy with an average price target of $22.00, implying a 48.7% upside from current levels. In a report issued on January 19, Truist Financial also maintained a Buy rating on the stock with a $22.00 price target.
Nemaura Medical (NMRD)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Nemaura Medical today and set a price target of $8.00. The company’s shares closed last Tuesday at $2.45.
According to TipRanks.com, Chen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nemaura Medical with a $10.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIIB:
- Ionis confirms FDA to hold advisory committee meeting on tofersen NDA
- Biogen says FDA to convene advisory committee meeting for tofersen
- Donanemab CRL a ‘positive headline’ for Biogen’s Leqembi, says William Blair
- Eisai submits marketing authorization application for lecanemab in Japan
- FDA Commissioner defends FDA’s approval of Biogen’s Aduhelm, WSJ reports
